|
|
|
Perspectives on a collaborative Canada-China research program on diagnostic biomarkers for pre-dementia stages of Alzheimer’s disease |
| Serge Gauthier1*, Jianping Jia2-7, Sylvie Belleville8, Simon Cloutier1,8, Dessa Sadovnick9,10, Colleen Guimond9, Laura Robb1, Mario Masellis11,12, Guy A Rouleau13, Liyong Wu14, Pedro Rosa-Neto1 |
1. McGill Center for Studies in Aging, Douglas Mental Health Research Institute, Montreal H4H IR3, Canada
2. Innovation Center for Neurological Disorders, Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
3. Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing 100053, China
4. Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing 100053, China
5. Center of Alzheimer’s Disease, Beijing Institute for Brain Disorders, Beijing 100053, China
6. Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing 100053, China
7. National Clinical Research Center for Geriatric Disorders, Beijing 100053, China
8. Institut Universitaire de Gériatrie de Montréal, Montréal H3W IW5, Canada
9. Department of Medical Genetics, University of British Columbia, Vancouver V6T IZ4, Canada
10. Division of Neurology, Department of Medical Genetics, University of British Columbia, Vancouver V6T IZ4, Canada
11. Division of Neurology/Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Toronto M5S 3H7, Canada
12. Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto M4N 3M5, Canada
13. Montreal Neurological Institute, Montréal H3A 2B4, Canada
14. Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China |
|
|
|
|
Abstract As biomarkers are important in the early diagnosis of Alzheimer's disease (AD), the first collaborative work of recruiting early-onset familial AD (EOFAD) families in Canada and China was initiated in 2012. The registration networks have collected hundreds of pedigrees, for which genetic screening, neuropsychological tests and amyloid and tau imaging was used to study diagnostic biomarkers for preclinical and mild cognitive impairment (MCI) stages of AD. Besides identifying pedigrees with novel mutations in presenilins (PSENs)/amyloid precursor protein (APP), the program has benefited training of Chinese research fellows, AD clinical trials for prevention, the ethical concerns for clinical findings, and other collaborative projects with Chinese investigators. Further research of the collaborative program may facilitate the testing and clinical use of novel treatments for EOFAD and late onset AD and contribute to dementia prevention strategies in Canada and China.
|
| Keywords
registration network
early-onset familial Alzheimer’s disease (EOFAD)
mutation
neuropsychological testing
|
|
Issue Date: 25 November 2017
|
|
| Cite this article: |
|
Serge Gauthier, Jianping Jia, Sylvie Belleville, Simon Cloutier, Dessa Sadovnick, Colleen Guimond, Laura Robb, Mario Masellis, Guy A Rouleau, Liyong Wu, Pedro Rosa-Neto. Perspectives on a collaborative Canada-China research program on diagnostic biomarkers for pre-dementia stages of Alzheimer’s disease[J]. Journal of Translational Neuroscience,2017, 2(3): 1-6.
|
|
|
|
| URL: |
https://academic.hep.com.cn/jtn/EN/10.3868/j.issn.2096-0689.2017.03.001
https://academic.hep.com.cn/jtn/EN/Y2017/V2/I3/1
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
